Analysis of the SH3-binding region of HIV-1 nef: partial functional defects introduced by mutations in the polyproline helix and the hydrophobic pocket.
An SH3-binding domain within the Nef protein of primate lentiviruses has been reported to be important to viral replication and infectivity and dispensable for CD4 downregulation, but its precise role remains unclear. This study investigates the effects of mutations in both the polyproline helix and in the hydrophobic pocket that constitute the SH3-binding domain of Nef. The data demonstrate that the well-studied mutation of the central prolines is only partially disruptive to viral infectivity and replication. The central prolines also make a subtle contribution to the efficiency of CD4 downregulation, detectable only using low levels of Nef expression. Mutation of a conserved arginine in the polyproline helix abrogated more completely Nef-mediated enhancement of viral infectivity; this mutation also adversely affected CD4 downregulation at low levels of Nef expression. Only the R77A mutation substantially impaired downregulation of class I MHC. However, mutation of the central prolines and of R77 yielded proteins that were expressed less efficiently than wild-type Nef. The R77A mutant was expressed most poorly, compatible with its defective phenotypes in all assays. Mutations of the hydrophobic pocket were minimally detrimental to both the virologic and the receptor modulatory functions of Nef. Taken together, this analysis suggests that mutations in the SH3-binding domain do not abrogate fully any Nef-associated phenotype in the absence of detrimental effects on protein expression. We suggest that mutations in this domain can introduce incomplete effects caused by subtle impairments to protein expression; these effects may appear selective under certain experimental conditions due to different sensitivities of the assays to the level of Nef expression.
Craig
H M
HM
Department of Medicine, University of California, San Diego, CA, USA.
Pandori
M W
MW
Riggs
N L
NL
Richman
D D
DD
Guatelli
J C
JC
D000818:Animals; D001665:Binding Sites / Q000235:genetics; D015704:CD4 Antigens / Q000096:biosynthesis; D015536:Down-Regulation / Q000276:immunology; D015693:Gene Products, nef / Q000096:biosynthesis / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics* / Q000472:pathogenicity / Q000502:physiology; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis; D016297:Mutagenesis, Site-Directed; D010455:Peptides / Q000235:genetics*; D017433:Protein Structure, Secondary; D014771:Virion / Q000235:genetics / Q000472:pathogenicity; D014779:Virus Replication / Q000235:genetics; D054311:nef Gene Products, Human Immunodeficiency Virus; D018909:src Homology Domains / Q000235:genetics*
D015704:CD4 Antigens; D015693:Gene Products, nef; D015395:Histocompatibility Antigens Class I; D010455:Peptides; D054311:nef Gene Products, Human Immunodeficiency Virus; C011083:polyproline